AstraZeneca’s immunotherapy drug wins key lung cancer approval – Reuters
Reuters |
AstraZeneca's immunotherapy drug wins key lung cancer approval
Reuters LONDON (Reuters) – AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. FILE PHOTO: A sign is … Imfinzi Approved to Reduce Risk of NSCLC Progression |
